Skip to content

Study · Animal study (in vivo) · rat · 2012

13 results

Pentadecapeptide BPC 157 reduces bleeding time and thrombocytopenia after amputation in rats treated with heparin, warfarin or aspirin.

Stupnisek M, Franjic S, Drmic D, Hrelec M, Kolenc D, Radic B, Bojic D, Vcev A, Seiwerth S, Sikiric P

Thrombosis research15 Aug 2011Cited by 59 (Europe PMC)

PMID21840572 (opens in a new tab)DOI10.1016/j.thromres.2011.07.035 (opens in a new tab)PepBankPUB-21840572
Publisher pagePubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, BPC‑157 reduced bleeding time after tail amputation alone.

    In plain wordsIn rats, BPC‑157 shortened bleeding time after tail amputation.

    Peptide
    BPC-157
    Outcome
    DecreaseBleeding time after tail amputation alone
    Study

    ratn: not reported in source

    Tail amputation with or without heparin, warfarin or aspirin
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 µg/kg, 10 ng/kg · intravenous, intraperitoneal or intragastric (follows the bleeding agent)As given in this study (rat).

    Source sentences

    Summary
    Here, in rats, BPC 157 (10 μg/kg, 10 ng/kg) improved always reduced bleeding time and amount of bleeding after (tail) amputation only, heparin (250 mg/kg, 25mg/kg, 10mg/kg i.v.), warfarin (1.5mg/kg i.g. once daily for 3 consecutive days), aspirin (0.1g/kg i.g. (once daily/3 consecutive days) or 1.0…
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats, BPC‑157 reduced the amount of bleeding after tail amputation alone.

    In plain wordsIn rats, BPC‑157 reduced blood loss after tail amputation.

    Peptide
    BPC-157
    Outcome
    DecreaseAmount of bleeding after tail amputation alone
    Study

    ratn: not reported in source

    Tail amputation with or without heparin, warfarin or aspirin
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 µg/kg, 10 ng/kg · intravenous, intraperitoneal or intragastric (follows the bleeding agent)As given in this study (rat).

    Source sentences

    Summary
    Here, in rats, BPC 157 (10 μg/kg, 10 ng/kg) improved always reduced bleeding time and amount of bleeding after (tail) amputation only, heparin (250 mg/kg, 25mg/kg, 10mg/kg i.v.), warfarin (1.5mg/kg i.g. once daily for 3 consecutive days), aspirin (0.1g/kg i.g. (once daily/3 consecutive days) or 1.0…
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats given heparin, BPC‑157 reduced bleeding time after amputation.

    In plain wordsIn rats given the blood thinner heparin, BPC‑157 shortened bleeding time after amputation.

    Peptide
    BPC-157
    Outcome
    DecreaseBleeding time after amputation with heparin
    Study

    ratn: not reported in source

    Tail amputation with or without heparin, warfarin or aspirin
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 µg/kg, 10 ng/kg · intravenous, intraperitoneal or intragastric (follows the bleeding agent)As given in this study (rat).

    Source sentences

    Summary
    Here, in rats, BPC 157 (10 μg/kg, 10 ng/kg) improved always reduced bleeding time and amount of bleeding after (tail) amputation only, heparin (250 mg/kg, 25mg/kg, 10mg/kg i.v.), warfarin (1.5mg/kg i.g. once daily for 3 consecutive days), aspirin (0.1g/kg i.g. (once daily/3 consecutive days) or 1.0…
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats given heparin, BPC‑157 reduced the amount of bleeding after amputation.

    In plain wordsIn rats given the blood thinner heparin, BPC‑157 reduced blood loss after amputation.

    Peptide
    BPC-157
    Outcome
    DecreaseAmount of bleeding after amputation with heparin
    Study

    ratn: not reported in source

    Tail amputation with or without heparin, warfarin or aspirin
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 µg/kg, 10 ng/kg · intravenous, intraperitoneal or intragastric (follows the bleeding agent)As given in this study (rat).

    Source sentences

    Summary
    Here, in rats, BPC 157 (10 μg/kg, 10 ng/kg) improved always reduced bleeding time and amount of bleeding after (tail) amputation only, heparin (250 mg/kg, 25mg/kg, 10mg/kg i.v.), warfarin (1.5mg/kg i.g. once daily for 3 consecutive days), aspirin (0.1g/kg i.g. (once daily/3 consecutive days) or 1.0…
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats given warfarin, BPC‑157 reduced bleeding time after amputation.

    In plain wordsIn rats given the blood thinner warfarin, BPC‑157 shortened bleeding time after amputation.

    Peptide
    BPC-157
    Outcome
    DecreaseBleeding time after amputation with warfarin
    Study

    ratn: not reported in source

    Tail amputation with or without heparin, warfarin or aspirin
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 µg/kg, 10 ng/kg · intravenous, intraperitoneal or intragastric (follows the bleeding agent)As given in this study (rat).

    Source sentences

    Summary
    Here, in rats, BPC 157 (10 μg/kg, 10 ng/kg) improved always reduced bleeding time and amount of bleeding after (tail) amputation only, heparin (250 mg/kg, 25mg/kg, 10mg/kg i.v.), warfarin (1.5mg/kg i.g. once daily for 3 consecutive days), aspirin (0.1g/kg i.g. (once daily/3 consecutive days) or 1.0…
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats given warfarin, BPC‑157 reduced the amount of bleeding after amputation.

    In plain wordsIn rats given the blood thinner warfarin, BPC‑157 reduced blood loss after amputation.

    Peptide
    BPC-157
    Outcome
    DecreaseAmount of bleeding after amputation with warfarin
    Study

    ratn: not reported in source

    Tail amputation with or without heparin, warfarin or aspirin
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 µg/kg, 10 ng/kg · intravenous, intraperitoneal or intragastric (follows the bleeding agent)As given in this study (rat).

    Source sentences

    Summary
    Here, in rats, BPC 157 (10 μg/kg, 10 ng/kg) improved always reduced bleeding time and amount of bleeding after (tail) amputation only, heparin (250 mg/kg, 25mg/kg, 10mg/kg i.v.), warfarin (1.5mg/kg i.g. once daily for 3 consecutive days), aspirin (0.1g/kg i.g. (once daily/3 consecutive days) or 1.0…
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats given aspirin, BPC‑157 reduced bleeding time after amputation.

    In plain wordsIn rats given aspirin, BPC‑157 shortened bleeding time after amputation.

    Peptide
    BPC-157
    Outcome
    DecreaseBleeding time after amputation with aspirin
    Study

    ratn: not reported in source

    Tail amputation with or without heparin, warfarin or aspirin
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 µg/kg, 10 ng/kg · intravenous, intraperitoneal or intragastric (follows the bleeding agent)As given in this study (rat).

    Source sentences

    Summary
    Here, in rats, BPC 157 (10 μg/kg, 10 ng/kg) improved always reduced bleeding time and amount of bleeding after (tail) amputation only, heparin (250 mg/kg, 25mg/kg, 10mg/kg i.v.), warfarin (1.5mg/kg i.g. once daily for 3 consecutive days), aspirin (0.1g/kg i.g. (once daily/3 consecutive days) or 1.0…
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rats given aspirin, BPC‑157 reduced the amount of bleeding after amputation.

    In plain wordsIn rats given aspirin, BPC‑157 reduced blood loss after amputation.

    Peptide
    BPC-157
    Outcome
    DecreaseAmount of bleeding after amputation with aspirin
    Study

    ratn: not reported in source

    Tail amputation with or without heparin, warfarin or aspirin
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 µg/kg, 10 ng/kg · intravenous, intraperitoneal or intragastric (follows the bleeding agent)As given in this study (rat).

    Source sentences

    Summary
    Here, in rats, BPC 157 (10 μg/kg, 10 ng/kg) improved always reduced bleeding time and amount of bleeding after (tail) amputation only, heparin (250 mg/kg, 25mg/kg, 10mg/kg i.v.), warfarin (1.5mg/kg i.g. once daily for 3 consecutive days), aspirin (0.1g/kg i.g. (once daily/3 consecutive days) or 1.0…
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In rats given heparin, warfarin or aspirin, and in normal rats, BPC‑157 gave a lesser fall in platelet count.

    In plain wordsIn rats given heparin, warfarin or aspirin, and in normal rats, BPC‑157 led to a smaller drop in platelet count.

    Peptide
    BPC-157
    Outcome
    DecreaseFall in platelet count
    Study

    ratn: not reported in source

    Tail amputation with or without heparin, warfarin or aspirin
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 µg/kg, 10 ng/kg · intravenous, intraperitoneal or intragastric (follows the bleeding agent)As given in this study (rat).

    Source sentences

    Summary
    All heparin-, warfarin-, and aspirin-rats and normal-rats that received BPC 157 exhibited lesser fall in platelets count.
    1 context sentence
    Summary · context
    Here, in rats, BPC 157 (10 μg/kg, 10 ng/kg) improved always reduced bleeding time and amount of bleeding after (tail) amputation only, heparin (250 mg/kg, 25mg/kg, 10mg/kg i.v.), warfarin (1.5mg/kg i.g. once daily for 3 consecutive days), aspirin (0.1g/kg i.g. (once daily/3 consecutive days) or 1.0…
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In rats given 10 mg/kg heparin, BPC‑157 attenuated the over-increased APTT values.

    In plain wordsIn rats given a high dose of heparin, BPC‑157 reduced the raised clotting time measure APTT.

    Peptide
    BPC-157
    Outcome
    DecreaseAPTT in heparin rats
    Study

    ratn: not reported in source

    Tail amputation with or without heparin, warfarin or aspirin
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 µg/kg, 10 ng/kg · intravenous, intraperitoneal or intragastric (follows the bleeding agent)As given in this study (rat).

    Source sentences

    Summary
    BPC 157 attenuated over-increased APTT-, TT-values in 10mg/kg heparin-rats
    1 context sentence
    Summary · context
    Here, in rats, BPC 157 (10 μg/kg, 10 ng/kg) improved always reduced bleeding time and amount of bleeding after (tail) amputation only, heparin (250 mg/kg, 25mg/kg, 10mg/kg i.v.), warfarin (1.5mg/kg i.g. once daily for 3 consecutive days), aspirin (0.1g/kg i.g. (once daily/3 consecutive days) or 1.0…
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In rats given 10 mg/kg heparin, BPC‑157 attenuated the over-increased TT values.

    In plain wordsIn rats given a high dose of heparin, BPC‑157 reduced the raised clotting time measure TT.

    Peptide
    BPC-157
    Outcome
    DecreaseTT in heparin rats
    Study

    ratn: not reported in source

    Tail amputation with or without heparin, warfarin or aspirin
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 µg/kg, 10 ng/kg · intravenous, intraperitoneal or intragastric (follows the bleeding agent)As given in this study (rat).

    Source sentences

    Summary
    BPC 157 attenuated over-increased APTT-, TT-values in 10mg/kg heparin-rats
    1 context sentence
    Summary · context
    Here, in rats, BPC 157 (10 μg/kg, 10 ng/kg) improved always reduced bleeding time and amount of bleeding after (tail) amputation only, heparin (250 mg/kg, 25mg/kg, 10mg/kg i.v.), warfarin (1.5mg/kg i.g. once daily for 3 consecutive days), aspirin (0.1g/kg i.g. (once daily/3 consecutive days) or 1.0…
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In rats given heparin, BPC‑157 did not influence heparin activity measured by the anti-Xa test.

    In plain wordsIn rats given heparin, BPC‑157 did not change how active the heparin was.

    Peptide
    BPC-157
    Outcome
    No significant changeHeparin activity (anti-Xa test)
    Study

    ratn: not reported in source

    Tail amputation with or without heparin, warfarin or aspirin
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 µg/kg, 10 ng/kg · intravenous, intraperitoneal or intragastric (follows the bleeding agent)As given in this study (rat).

    Source sentences

    Summary
    but did not influence heparin activity (anti-Xa test).
    1 context sentence
    Summary · context
    Here, in rats, BPC 157 (10 μg/kg, 10 ng/kg) improved always reduced bleeding time and amount of bleeding after (tail) amputation only, heparin (250 mg/kg, 25mg/kg, 10mg/kg i.v.), warfarin (1.5mg/kg i.g. once daily for 3 consecutive days), aspirin (0.1g/kg i.g. (once daily/3 consecutive days) or 1.0…
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In rats given heparin 25 mg/kg with right foot amputation, BPC‑157 markedly prolonged survival time.

    In plain wordsIn rats given heparin and a foot amputation, BPC‑157 clearly prolonged survival time.

    Peptide
    BPC-157
    Outcome
    IncreaseSurvival time in heparin rats
    Study

    ratn: not reported in source

    Tail amputation with or without heparin, warfarin or aspirin
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    10 µg/kg, 10 ng/kg · intravenous, intraperitoneal or intragastric (follows the bleeding agent)As given in this study (rat).

    Source sentences

    Summary
    Also, BPC 157 markedly prolongs the survival time (heparin-rats, 25mg/kg, right foot amputation).
    1 context sentence
    Summary · context
    Here, in rats, BPC 157 (10 μg/kg, 10 ng/kg) improved always reduced bleeding time and amount of bleeding after (tail) amputation only, heparin (250 mg/kg, 25mg/kg, 10mg/kg i.v.), warfarin (1.5mg/kg i.g. once daily for 3 consecutive days), aspirin (0.1g/kg i.g. (once daily/3 consecutive days) or 1.0…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.